1
|
Sun Y, Bo Q, Mao Z, Tian Q, Dong F, Li L, Wang C. Different levels of prepulse inhibition among patients with first-episode schizophrenia, bipolar disorder and major depressive disorder. J Psychiatry Neurosci 2024; 49:E1-E10. [PMID: 38238035 PMCID: PMC10803101 DOI: 10.1503/jpn.230083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 08/10/2023] [Accepted: 09/27/2023] [Indexed: 01/23/2024] Open
Abstract
BACKGROUND Deficits in prepulse inhibition may be a common feature in first-episode schizophrenia, bipolar disorder (BD) and major depressive disorder (MDD). We sought to explore the levels and viability of prepulse inhibition to differentiate first-episode schizophrenia, BD and MDD in patient populations. METHODS We tested patients with first-episode schizophrenia, BD or MDD and healthy controls using prepulse inhibition paradigms, namely perceived spatial co-location (PSC-PPI) and perceived spatial separation (PSS-PPI). RESULTS We included 53 patients with first-episode schizophrenia, 30 with BD and 25 with MDD, as well as 82 healthy controls. The PSS-PPI indicated that the levels of prepulse inhibition were smallest to largest, respectively, in the first-episode schizophrenia, BD, MDD and control groups. Relative to the healthy controls, the prepulse inhibition deficits in the first-episode schizophrenia group were significant (p < 0.001), but the prepulse inhibitions were similar between patients with BD and healthy controls, and between patients with MDD and healthy controls. The receiver operating characteristic curve analysis showed that PSS-PPI (area under the curve [AUC] 0.73, p < 0.001) and latency (AUC 0.72, p < 0.001) were significant for differentiating patients with first-episode schizophrenia or BD from healthy controls. LIMITATIONS The demographics of the 4 groups were not ideally matched. We did not perform cognitive assessments. The possible confounding effect of medications on prepulse inhibition could not be eliminated. CONCLUSION The level of prepulse inhibition among patients with first-episode schizophrenia was the lowest, with levels among patients with BD, patients with MDD and healthy controls increasingly higher. The PSS-PPI paradigm was more effective than PSC-PPI to recognize deficits in prepulse inhibition. These results provide a basis for further research on biological indicators that can assist differential diagnoses in psychosis.
Collapse
Affiliation(s)
- Yue Sun
- From the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li)
| | - Qijing Bo
- From the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li)
| | - Zhen Mao
- From the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li)
| | - Qing Tian
- From the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li)
| | - Fang Dong
- From the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li)
| | - Liang Li
- From the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li)
| | - Chuanyue Wang
- From the National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the Advanced Innovation Center for Human Brain Protection, Capital Medical University (Sun, Bo, Mao, Tian, Dong, Wang); the School of Psychological and Cognitive Sciences and Beijing Key Laboratory of Behavior and Mental Health, Peking University, Beijing, China (Li)
| |
Collapse
|
2
|
Boele HJ, Jung C, Sherry S, Roggeveen LEM, Dijkhuizen S, Öhman J, Abraham E, Uvarov A, Boele CP, Gultig K, Rasmussen A, Vinueza-Veloz MF, Medina JF, Koekkoek SKE, De Zeeuw CI, Wang SSH. Accessible and reliable neurometric testing in humans using a smartphone platform. Sci Rep 2023; 13:22871. [PMID: 38129487 PMCID: PMC10739701 DOI: 10.1038/s41598-023-49568-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2023] [Accepted: 12/09/2023] [Indexed: 12/23/2023] Open
Abstract
Tests of human brain circuit function typically require fixed equipment in lab environments. We have developed a smartphone-based platform for neurometric testing. This platform, which uses AI models like computer vision, is optimized for at-home use and produces reproducible, robust results on a battery of tests, including eyeblink conditioning, prepulse inhibition of acoustic startle response, and startle habituation. This approach provides a scalable, universal resource for quantitative assays of central nervous system function.
Collapse
Affiliation(s)
- H J Boele
- Princeton Neuroscience Institute, Princeton, USA.
- Department of Neuroscience, Erasmus MC, Rotterdam, The Netherlands.
| | - C Jung
- Princeton Neuroscience Institute, Princeton, USA
| | - S Sherry
- Princeton Neuroscience Institute, Princeton, USA
| | - L E M Roggeveen
- Department of Neuroscience, Erasmus MC, Rotterdam, The Netherlands
- Department of Neuroscience, Vrije Universiteit, Amsterdam, The Netherlands
| | - S Dijkhuizen
- Department of Neuroscience, Erasmus MC, Rotterdam, The Netherlands
| | - J Öhman
- Department of Clinical Sciences, Lund University, Lund, Sweden
| | - E Abraham
- Princeton Neuroscience Institute, Princeton, USA
| | | | - C P Boele
- Department of Neuroscience, Erasmus MC, Rotterdam, The Netherlands
| | - K Gultig
- Department of Neuroscience, Erasmus MC, Rotterdam, The Netherlands
| | - A Rasmussen
- Department of Clinical Sciences, Lund University, Lund, Sweden
| | - M F Vinueza-Veloz
- Department of Neuroscience, Erasmus MC, Rotterdam, The Netherlands
- Department of Community Medicine and Global Health, University of Oslo, Oslo, Norway
| | - J F Medina
- Department of Neuroscience, Baylor College of Medicine, Houston, USA
| | - S K E Koekkoek
- Department of Neuroscience, Erasmus MC, Rotterdam, The Netherlands
| | - C I De Zeeuw
- Department of Neuroscience, Erasmus MC, Rotterdam, The Netherlands
- Netherlands Institute for Neuroscience, Royal Academy of Arts and Sciences, Amsterdam, The Netherlands
| | - S S-H Wang
- Princeton Neuroscience Institute, Princeton, USA.
| |
Collapse
|
3
|
Yildiz Taskiran S, Taskiran M, Unal G, Bozkurt NM, Golgeli A. The long-lasting effects of aceclofenac, a COX-2 inhibitor, in a Poly I:C-Induced maternal immune activation model of schizophrenia in rats. Behav Brain Res 2023; 452:114565. [PMID: 37414224 DOI: 10.1016/j.bbr.2023.114565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Revised: 07/01/2023] [Accepted: 07/02/2023] [Indexed: 07/08/2023]
Abstract
It is well established that rats exposed to inflammation during pregnancy or the perinatal period have an increased chance of developing schizophrenia-like symptoms and behaviors, and people with schizophrenia also have raised levels of inflammatory markers. Therefore, there is evidence supporting the idea that anti-inflammatory drugs may have therapeutic benefits. Aceclofenac is a nonsteroidal anti-inflammatory drug that has anti-inflammatory properties and is used clinically to treat inflammatory and painful processes such as osteoarthritis and rheumatoid arthritis, making it a potential candidate for preventive or adjunctive therapy in schizophrenia. This study therefore examined the effect of aceclofenac in a maternal immune activation model of schizophrenia, in which polyinosinic-polycytidylic acid (Poly I:C) (8 mg/kg, i.p.) was administered to pregnant rat dams. Young female rat pups received daily aceclofenac (5, 10, and 20 mg/kg, i.p., n = 10) between postnatal day 56 and 76. The effects of aceclofenac were compared with assessment of behavioral tests and ELISA results. During the postnatal days (PNDs) 73-76, behavioral tests were conducted in rats, and on PND 76, ELISA tests were performed to examine the changes in Tumor necrosis factor alpha (TNF-α), Interleukin-1β (IL-1β), Brain-derived neurotrophic factor (BDNF), and nestin levels. Aceclofenac treatment reversed deficits in prepulse inhibition, novel object recognition, social interaction, and locomotor activity tests. In addition, aceclofenac administration decreased TNF-α and IL-1β expression in the prefrontal cortex and hippocampus. In contrast, BDNF and nestin levels did not change significantly during treatment with aceclofenac. Taken together, these results suggest that aceclofenac may be an alternative therapeutic adjunctive strategy to improve the clinical expression of schizophrenia in the further studies.
Collapse
Affiliation(s)
| | - Mehmet Taskiran
- Department of Biology, Faculty of Science, Erciyes University, Kayseri, Türkiye
| | - Gokhan Unal
- Department of Pharmacology, Faculty of Pharmacy, Erciyes University, Kayseri, Türkiye
| | - Nuh Mehmet Bozkurt
- Department of Pharmacology, Faculty of Pharmacy, Erciyes University, Kayseri, Türkiye
| | - Asuman Golgeli
- Department of Physiology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye
| |
Collapse
|